Shishir Mani Pant

Shishir Mani Pant

Auto-generated profile, based on publicly available information

Shishir Mani Pant

Harvard Ludwig Center and Laboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2021 in EMBO Reports
Verified
Journal Article
Open access
PDF file
DBDenis Belitškin
Denis Belitškin
SPShishir M Pant
Shishir M Pant
PMPauliina Munne
Pauliina Munne
ISIlida Suleymanova
Ilida Suleymanova
KBKati Belitškina
Kati Belitškina
JKJuha Klefström
Juha Klefström
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

18 January 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
TTTopi A. Tervonen
Topi A. Tervonen
SPShishir M. Pant
Shishir M. Pant
DBDenis Belitškin
Denis Belitškin
JEJohanna I. Englund
Johanna I. Englund
KNKatja Närhi
Katja Närhi
JKJuha Klefström
Juha Klefström
Ras proteins play a causal role in human cancer by activating multiple pathways that promote cancer growth and invasion. However, little is known about how Ras induces the first diagnostic features of invasion in solid tumors, including loss of epithelial integrity and breaching of the basement membrane (BM). In this study, we found that oncogenic Ras strongly promotes the activation of hepsin, a member of the hepsin/TMPRSS type II transmembrane serine protease family. Mechanistically, the Ras-dependent hepsin activation was mediated via Raf–MEK–ERK signaling, which controlled hepsin protein stability through the heat shock transcription factor-1 stress pathway. In Ras-transformed three-dimensional mammary epithelial culture, ablation of hepsin restored desmosomal cell–cell junctions, hemidesmosomes, and BM integrity and epithelial cohesion. In tumor xenografts harboring mutant KRas, silencing of hepsin increased local invasion concomitantly with accumulation of collagen IV. These findings suggest that hepsin is a critical protease for Ras-dependent tumorigenesis, executing cell–cell and cell–matrix pathologies important for early tumor dissemination. Significance: These findings identify the cell-surface serine protease hepsin as a potential therapeutic target for its role in oncogenic Ras-mediated deregulation of epithelial cell–cell and cell–matrix interactions and cohesion of epithelial structure.

24 June 2025 in bioRxiv
Verified
Preprint
Open access
TVTuulia Vallius
Tuulia Vallius
YSYingxiao Shi
Yingxiao Shi
ENEdward Novikov
Edward Novikov
SPShishir M Pant
Shishir M Pant
RPRoxanne Pelletier
Roxanne Pelletier
PSPeter K Sorger
Peter K Sorger
Localized cutaneous melanoma can be cured by excision but success critically depends on early detection and risk assessment of primary lesions. However, their initiation, progression, and immunology remain poorly understood, partly due to high intra- and inter-tumor heterogeneity. We studied this heterogeneity using spatial profiling in over 300 histological domains, each representing a single progression stage, and found that 200-600 cell neighborhoods from a single melanoma can be as different in RNA and protein expression as neighborhoods from different tumors. These differences are not stochastic, however, and disease progression can be mapped at the neighborhood level onto a cell state landscape defined by the activity of the melanocyte master regulator MITF and genes associated with a dedifferentiated neural crest phenotype. Position in this landscape is influenced by proximity to immune cells, perivascular environments, and other tissue features, but no single association is absolute, giving rise to complex spatial patterns.

22 October 2025 in bioRxiv
Verified
Preprint
Open access
JWJason B. Williams
Jason B. Williams
SPShishir M. Pant
Shishir M. Pant
AKAlexander L. Kley
Alexander L. Kley
BRBharat A. Rajmalani
Bharat A. Rajmalani
CYClarence Yapp
Clarence Yapp
TKThomas S. Kupper
Thomas S. Kupper
How the immune system surveys nascent tumors and how this surveillance is subverted remain poorly understood. Using high-plex cyclic immunofluorescence and 3D imaging, we identified regulatory T (Treg) cells that co-localize with tissue-resident memory (T RM )-like T cells in early-stage human melanoma. In an autochthonous Braf/PTEN melanoma model expressing a defined tumor antigen, the initial CD8 + T cell infiltrate adopts a CD103 + CD101 + T RM -like fate, establishing active immunosurveillance within nascent lesions. T RM -like cells dominate early tumors, occupy a stable epidermal niche, express effector molecules, and initiate T cell recruitment. However, Treg cells adopt a parallel tissue-resident phenotype, co-localizing with T RM -like cells and restraining both cytotoxic and sentinel functions. Tumor-site-specific Treg depletion reactivated T RM -like cells, drove robust T cell recruitment, expanded tumor-specific responses, and limited tumor growth. These findings reveal how early immunosurveillance is established through tissue-resident programs and identify Treg co-option of this response as a critical mechanism of tumor immune evasion. One Sentence Summary: Nascent melanoma imprints a tissue-resident program on the initial CD8 + T cell infiltrate, which is suppressed by regulatory T cells as a critical checkpoint in immune evasion.

15 December 2025 in bioRxiv
Verified
Preprint
Open access
YSYingxiao Shi
Yingxiao Shi
ZMZoltan Maliga
Zoltan Maliga
TVTuulia Vallius
Tuulia Vallius
SPShishir M Pant
Shishir M Pant
RPRoxanne Pelletier
Roxanne Pelletier
PSPeter Karl Sorger
Peter Karl Sorger
Tumor dormancy is thought to enable cancer recurrence, but the settings and mechanisms of dormancy in patients are poorly characterized. Both immunogenic tumor mass dormancy, involving continued tumor cell proliferation and balanced immune-mediated cell death, and cell-level quiescence have been observed in preclinical models. Here, we demonstrate the existence of mass dormancy rather than quiescence in long-term stable residual lesions in melanoma patients treated with immune checkpoint inhibitors (ICI). In a large stable lesion subjected to detailed spatial profiling, the proportion of proliferating tumor cells is similar to that in site-matched tumors from patients progressing after ICI. Residual stable lesions from other patients, judged to contain only scar tissue upon clinical pathology review, also contained nests of dividing tumor cells surrounded by active immune cells. These findings demonstrate the presence of viable tumor cells and mass dormancy in persistent stable lesions, a finding with implications for disease monitoring and management.

6 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
YSYingxiao Shi
Yingxiao Shi
PSPriyanka Sharma
Priyanka Sharma
JLJia-Ren Lin
Jia-Ren Lin
ADAikaterini Dedeilia
Aikaterini Dedeilia
TVTuulia Vallius
Tuulia Vallius
GBGenevieve Boland
Genevieve Boland
Mucosal melanoma is a rare, lethal melanoma subtype with distinct genetics and limited benefit from immunotherapy. To define features associated with mucosal melanoma clinical outcomes, we assembled a large, multimodally profiled cohort spanning primary and metastatic disease. Compared with cutaneous melanoma, primary mucosal melanoma showed greater genomic heterogeneity, ploidy and aneuploidy, and a more dedifferentiated, proliferative transcriptional state. Analysis of genomic sequencing of 339 patients with mucosal melanoma identified four mutually exclusive genomic subtypes: CDK4/MDM2/CCND1, SF3B1-mutated, TP53/ATRX, and mucosal melanoma Triple WT, associated with distinct anatomic sites but similar outcomes. In the tumor microenvironment, we observed reduced T cell infiltration and increased CD163 + tumor-associated macrophages in mucosal melanoma relative to cutaneous melanoma. In matched longitudinal samples, CD163 + tumor-associated macrophages increased with disease progression and immunotherapy resistance. CD163 + tumor-associated macrophages engaged non-regulatory T cells through GAL9–TIM-3 interactions, nominating TIM-3 blockade as a therapeutic strategy for mucosal melanoma. These findings define the distinct aggressive biology of mucosal melanoma and highlight potential therapeutic targets and mechanisms of immune resistance.